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2.1 Introduction
A model is a representation of an underlying physical–chemical phenomenon.
In the pharmaceutical industry, mathematical‐based models can be applied at
all stages of development, starting with formulation design, continuing through
process development and scale‐up, and extending into process monitoring and
control of the commercial process. Implementation of models offers many
benefits. These include, but are not limited to, (i) enhanced process understanding, (ii) reduction of experimentation cost, and (iii) improvement of
productivity and product quality.

2.2 Overview of Models
Models can be broadly categorized as either qualitative or quantitative. The
focus of this chapter is quantitative models. These can be classified into three
broad areas: mechanistic, empirical, and hybrid. As illustrated in the knowledge pyramid in Figure 2.1, overall understanding and the information needed
to derive from these models increases from empirical to mechanistic models.
Mechanistic models are based on first principles, capture the underlying
physical/chemical phenomena through sets of equations, and can be time
independent (i.e., steady‐state) or dynamic. As indicated by Singh et al.
[1], mechanistic models can be an excellent way to represent process knowledge. In such models, the input–output dynamics in a unit operation can be
represented by a set of differential equations. Model building necessitates the
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Figure 2.1 Knowledge pyramid for developing mathematical models.

availability of balance equations (e.g., mass and energy balance equations),
constitutive equations, and an understanding of the constraints. Since
mechanistic models are a true representation of the underlying phenomenon, predictions from these models can sometimes be extrapolated beyond
the range covered by input data, depending on the validity of the underlying
assumptions. Typically, the bottleneck in developing mechanistic models is
coming up with equations as well as associated parameters that accurately
represent the system.
Empirical modeling approaches also can be used to represent input–output
dynamics. These models are particularly useful for complex systems where it is
not feasible to develop mechanistic models. Empirical models treat a system as
a “black box” and do not typically describe the underlying physical–chemical
phenomena. These models represent input–output dynamics of a system
solely in terms of observational data. One of the limitations of empirical models
is that the range of applicability of these models is limited to the variation
represented in the data that was used to derive the model. Hence, predictions
from these models cannot be reliably extrapolated beyond the range covered
by the input data. On the other hand, the advantage of empirical models is that
they can be relatively easy to put together and solve, as compared with mechanistic models.
In the pharmaceutical world, empirical models are typically used for process
understanding and control, such as to program software sensors associated
with process analytical technology (PAT)‐based tools. While mechanistic
models have a distinct advantage of a wide range of predictive potential, not all
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processes associated with the pharmaceutical industry are understood well
enough to allow them to be modeled using first principles.
Philosophically, however, there are few true mechanistic or empirical
models. All mechanistic models have a degree of empiricism in them (e.g.,
modeling assumptions), while all empirical models have a mechanistic
element (e.g., rationale for selection of input parameters that are used to
derive the models). In general, models are classified into either category
depending on the preponderance of mechanistic or empirical components
in the model. Following this philosophy, models can be classified as semiempirical or hybrid if they have relatively equal proportion of mechanistic
and empirical elements.
Hybrid models are a combination of mechanistic and empirical models. As
elucidated by Gernaey et al. [2], the approach is to include all available process
knowledge in a first‐principles‐based model, where the gaps in process knowledge are then represented on the basis of empirical (i.e., data‐driven) approaches
utilizing available experimental data. Examples of hybrid models are scale‐up
correlations, where the form of the equation is derived from fundamental relations, while the constants are fit from experimental data.
As shown in Figure 2.2, each model category has several potential approaches
and mathematical techniques.

Mechanistic

Exact solution/
thermodynamic

Computational
fluid dynamics
(CFD)

Discrete element
model (DEM)

Empirical

Chemometric
Multivariate
models (MV)

Scale-up equations

Neural network

Property estimation
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Regression model
Finite element
model (FEM)

Semi
empirical/hybrid

Probability based

Figure 2.2 Schematic of types of models.
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Mechanistic models can include, but are not limited to, (i) models that
involve exact solution of equations representing the underlying physical–
chemical phenomena while treating the system as one entity; (ii) computational
fluid dynamics (CFD) approach, where intensive computational techniques are
used to simulate fluid movements while dividing the volume occupied by the
fluid into discrete cells (or the mesh); (iii) discrete element modeling (DEM)
approach, which involves rigorous computation to simulate the motion of
a collection of discrete particles of micrometer‐scale size and above; and
(iv) finite element model (FEM) that involves solving constitutive equations for
a domain by discretizing the domain into small elements or nodes.
Empirical models can include, but are not limited to, (i) regression correlations (linear or nonlinear) derived between a dependent variable and one or
more independent variables, (ii) statistically based latent variable (LV) models
that relate a set of manifest variables to a set of LVs (multivariate models and
chemometric models belong to this category), (iii) neural network models that
utilize nonlinear statistical modeling tools to represent complex relations
between inputs and outputs, (iv) probability‐based models in which the relationship between inputs and outputs is expressed in terms of probability
theory, and (v) in vitro–in vivo correlation (IV–IVC) models that describe the
relationship between an in vitro property of an extended release dosage form
and a relevant in vivo response, for example, plasma concentration. IV–IVC
models include regression correlation approach as well as principles of statistical moment analysis.
Scale‐up correlations based on dimensional analysis can be considered hybrid
models. Dimensional analysis is based on characterization of a process in terms of
dimensionless numbers. Dimensionless numbers involve a mechanistic component in identifying the factors that constitute them; however, the method of
derivation of these numbers may be regarded as empirical. The objective during
scale‐up is to keep the dimensionless numbers constant at various scales to ensure
consistency of product quality at all scales. An example of a hybrid modeling
approach is the model described by Chen et al. [3]. This model is used for predicting active pharmaceutical ingredient content uniformity for a drug product in
which the active is coated onto a core tablet. The model is based on a mechanistic
description of the spray coating process in a perforated coating pan and included
a number of parameters that were measured from experimental runs.

2.3 Role of Models in QbD
An example of a QbD implementation approach as outlined in ICH Q8 (R2) [4]
involves the following steps:
1) Identification of quality target product profile (QTPP), which ensures the
finished product’s quality, safety, and efficacy
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2)
3)
4)
5)
6)

Identification of critical to quality attributes (CQAs)
Risk assessment
Determination of design space
Implementation of the control strategy
Continual improvement

The following paragraphs describe how models can be used at every stage
of the QbD implementation approach by citing examples from published
literature. This compilation is not exhaustive of various types of models that
can be implemented to support QbD‐based development. Instead, a few
examples were selected from the literature to exemplify potential applicability
for each step.
2.3.1 CQA

A CQA is a physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to
ensure the desired drug product quality. CQAs are generally associated with
drug substance, excipients, intermediates, and drug product. CQAs of typical
drug substance include particle size, residual solvent level, impurity levels,
crystal form, and so on. In general, CQAs of a drug product are similar to the
attributes that are part of the specifications, such as assay, content uniformity,
dissolution, and impurity level.
One example using these models to better understand a CQA is the use of an
IV–IVC that can be used to establish the link between desired clinical performances, that is, bioavailability and dissolution. IV–IVC has been defined as a
predictive mathematical model describing the relationship between an in vitro
property of a dosage form and its in vivo response [5]. In Rossi et al. [6], it is
shown how IV–IVC data is used to develop and validate a dissolution test for
immediate release ritonavir soft gel capsules (Norvir®). With ritonavir being a
poorly soluble drug, dissolution is regarded as a predictor of in vivo performance, hence may be classified as a CQA. As shown in this chapter, a meaningful dissolution test (that includes test conditions as well as specification) for
Norvir soft gelatin capsules was developed using in vivo data. A significant linear level A correlation between in vitro and in vivo parameters was established.
2.3.2 Risk Assessment

As outlined in ICH Q9 [7], risk assessment consists of the identification of hazards and the analysis and evaluation of risks associated with exposure to those
hazards. Quality risk management is a systematic process for the assessment,
control, communication, and review of risks to the quality of the drug (medicinal) product across the product life cycle. During development, risk assessment
can be carried out to identify unit operations or drug substance synthetic steps
as well as material/process parameters that have an impact on the finished
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product attributes. The identified parameters can then be further evaluated via
either experiments or mathematical models or a combination of both.
Various quantitative or semiquantitative approaches can be used for risk
assessment. ICH Q9 lists several tools that can be used for risk assessment,
such as failure mode effects analysis (FMEA), failure mode effects and criticality analysis (FMECA), fault tree analysis (FTA), hazard analysis and critical
control points (HACCP), hazard operability analysis (HAZOP), preliminary
hazard analysis (PHA), and risk ranking and filtering.
Out of the listed tools, FMEA and FMECA can be regarded as semiquantitative approaches. These tools are commonly used for quality analysis of processes, such as those covered in six‐sigma approaches. In FMEA, the risk of
failure of each parameter is evaluated on the basis of frequency of occurrence
(O), probability that the failure would remain undetected (D), and its severity
(S). Each mode is then ranked by a group of cross‐functional experts on a linear
scale (e.g., a scale of 1–10), with a higher number representing a higher risk.
Once the occurrence, detection, and severity are determined, the net risk is
then estimated by calculating the risk priority number (RPN), which is a product
of the scores for O, D, and S. A high RPN implies a greater risk.
A review of the literature showed an example where FMEA technique was
implemented to improve the efficiency of a near‐infrared (NIR)‐based analytical
procedure [8]. In this chapter, an NIR analytical procedure that was used for
screening drugs for authenticity was subjected to an FMEA analysis. Each failure
mode was ranked on estimated frequency of occurrence (O), probability that the
failure would remain undetected later in the process (D), and severity (S), each
on a scale of 1–10. Failure risks were calculated by RPNs = O × D × S. Failure
modes with the highest RPN scores were subjected to corrective actions and the
FMEA was repeated. Human errors turned out to be the most common cause of
failure modes. Based on their findings, the authors recommended that for analytical method validation, risk analysis, for example, by FMEA, be carried out in
addition to the usual analytical validation, to help in detecting previously unidentified risks. In another case, FMEA was used to identify critical formulation
and process variables for a roller compaction process, and the information from
FMEA was then used to build a design space by Design of Experiment (DOE) [9].
2.3.3

Design Space

As defined in ICH Q8 (R2) [4], a design space is a multidimensional combination and interaction of input variables (e.g., material attributes) and process
parameters that have been demonstrated to provide assurance of quality.
Often, risk assessment techniques are used to identify parameters that define a
design space by identifying parameters that have a potential to impact the
CQA of a drug quality. A design space can be determined via experiments and
modeling at laboratory, pilot, and/or commercial scale. Design spaces can be
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defined for both drug substances and drug products. Modeling approaches
such as mechanistic, empirical, or hybrid can be used for design space development wherein as discussed in the following examples, models can be used to
support its various facets, including defining a design space at pilot scale based
on DOE data, scaling up pilot scale design space to commercial scale, and
understanding the limitations of the proposed design space.
a) Design space based on DOE data: As presented by Verma et al. [10], the
effects of key formulation process variables for a microfluidization unit
operation was investigated via fractional factorial statistically based DOE.
Microfluidization was used in the preparation of nanosuspensions for
poorly water‐soluble drugs. Multiple linear regression and ANOVA techniques were employed to analyze the data from the DOE, in order to identify and estimate the effect of important factors, to establish their
relationship with CQAs, and to create a design space and a predictive model
of the microfluidization unit operation. Interactions between the variables
were also depicted using contour plots.
Figure 2.3 shows a general approach for defining a design space based on
DOE data. A DOE is initially carried out in terms of multiple independent
input variables (i.e., inputs variables are all orthogonal to each other). Input
variables are selected on the basis of the magnitude of their potential impact
to product quality. Various options are available for DOE design, for example, full factorial and d‐optimal. Experiments are carried out in a random
fashion and response(s) is measured. Typically identified CQAs are measured as responses in a DOE. Data from the DOE is analyzed using statistical
approaches such as Pareto charts to identify the statistical significance of
input variables and their interactions to product quality. A regression correlation is then derived from the DOE data in terms of the significant input
variables. Design space can then be represented mathematically in terms of
the regression correlation or graphically, for example, as a contour surface.
b) Design space based on hybrid model: In this example, two mechanistic tablet film coating models were used for scale‐up of tablet film coating of an
established commercial immediate release product [11]. The models were
the following: (a) a thermodynamic film coating model based on the first
laws of thermodynamics and mass and energy balance principles that predicted exhaust air temperature and relative humidity on the basis of input
conditions and (b) a physics‐based film coating atomization model that
described the performance of atomizers utilized in the tablet coating process. The models were used to establish an acceptable range of process
parameters in a new film coater to match the proven acceptable range of
operating conditions in the existing pan coaters. These are considered as
hybrid models, since each model included some empirical parameters that
were fitted using experimental data, to minimize the residual sum of
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squared error between experimental data and model prediction. The established process parameters were then used to prioritize the experimental
design to minimize the number of required trial runs and to support optimization. The recommendations were then provided to the commercial site
to guide the design of scale‐up trials.
c) Design space based on integrated multivariate approach: In another case, a
design space was defined on the basis of DOE, optimization, and multivariate analysis (MVA) [12]. Initially, a screening DOE was carried out to identify the parameters that have an impact on the finished product’s CQA.
Following the screening DOE, an optimization DOE was carried out to
evaluate the effects of the design factors on manufacturability and final
product’s CQA such as tablet blend flow and tablet dissolution and to
establish a design space to ensure CQAs. Figure 2.4 is a schematic rendition
of the methodology for design space development and implementation, as
presented by Huang et al. [12].
As illustrated in Figure 2.4, design space was established as a response
surface model based on DOE data. In addition, an MVA using principal
component analysis (PCA) and partial least squares (PLS) was also carried
out using all the variables from the DOE campaigns, to study multivariate
relationships between all variables that include raw materials, intermediates, various unit operations, and final product. The multivariate techniques were complementary to DOE analysis and provided a representation of
all multivariate interactions in the process, based on the combinations
of all raw materials and process parameters. Findings from both DOE and
MVA were then used to define a control strategy for the product. As elucidated by Huang et al., the combined use of DOE and MVA offers a
robust mechanism to explain complex multivariate relationships. Since
DOEs in general deal with a limited number of experiments (due to practical limitation in the number of experiments), MVA can be considered as
complementary to DOE, providing additional information about the
product and processes.
d) Mechanistic model for scale‐up: In an example by Pandey et al. [13], a DEM
was developed to study the particle motion in pan coating. DEM simulates
the prediction of individual trajectories of particles using constitutive equations. By this approach, movement due to the contact forces from neighboring particles is accounted for. An advantage of this approach is that it
allows to study the changes in particle motion due to changes in operating
conditions (e.g., pan speed and pan load) as well as particle properties such
as tablet size, shape, and density. On the basis of DEM analysis, a modified
scale‐up relationship for the pan coater was proposed.
e) Monte Carlo‐based models for understanding uncertainty in design space: A
Monte Carlo‐based method was applied to simulate the propagation of
uncertainty in predictions performed with DOE‐based design space models
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by Kauffman et al. [14]. In this study, the design space was represented by a
polynomial model. The results of the simulations presented in this work
highlighted two major benefits from the application of Monte Carlo simulation for the propagation of uncertainty in design space models. First, the
simulations provided estimates of both the means and standard deviations
for the predicted values of CQA. With these quantities in hand, design
space was then specified on the basis of model predictions and product
quality specifications with statistically meaningful confidence levels.
Secondly, the simulations identified the process variable variances that have
the greatest influence on the product quality variance, which can be used to
prioritize control strategy and process improvement plans.
2.3.4 Control Strategy

In ICH Q10 [15], a control strategy is defined as a set of controls, derived from
current product and process understanding, that assure process performance
and product quality. ICH Q10 is a model for the pharmaceutical quality system
that can be implemented throughout the life cycle of the product. The objective of the control strategy is to ensure that desired quality product will be
manufactured. In general, a control strategy includes the following components: specifications for incoming materials and critical intermediates, ranges
for process parameters, in‐process monitoring and control, end‐product testing at release, and other elements as described in Q10 such as change management. Furthermore, a control strategy can evolve/change during the life cycle
of a product. Management of these changes is typically handled by the firm’s
change management procedures.
Models can be used in the implementation of a robust and efficient control
strategy. In general, such models have to be updated throughout the life cycle
of the product, and procedures for maintenance of these models are typically
captured in the firm’s change management system. Some examples of these
models to support control strategy are presented as follows:
a) LV‐based models for process control: In the example by Kourti [16], an LV
approach is used to support a feed‐forward control strategy. Using this
approach, when a deviation is detected in the measured quality of an intermediate that could affect finished product quality, a feed‐forward control
strategy could be used to adjust manufacturing parameters to produce the
desired quality of the finished product. An example of this approach is
adjustment of tablet compression parameters based on granule bulk
density. An LV model is built from multiple batch data to relate the finished
product quality in terms of compression parameter settings and intermediate material attributes, for example, granule density. This LV model, as
illustrated in Figure 2.5, shows the interaction between compression
process parameters and intermediate material attributes [17].
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Process

Raw material

Granule density

Finished product
quality

Figure 2.5 Approach for developing LV models for feed‐forward control. Source: Kourti [17].
Reproduced with permission of John Wiley & Sons.

In another example by García‐Munoz et al. [18], LV models were used to set
quality‐driven specifications for incoming raw materials. Such specifications accounted for the inherent variability in the process and the combined
effect of materials with process conditions onto product quality. Additionally,
Rathore et al. [19] demonstrated the usefulness of multivariate data analysis
techniques for optimizing biopharmaceutical manufacturing, process
scale‐up, process comparability, and process optimization.
b) Multivariate statistical process control (MSPC) model to support real‐time
release testing (RTRT): In ICH Q8 (R2), RTRT is defined as the ability to
evaluate and ensure the quality of in‐process and/or final product based on
process data, which typically include a valid combination of measured
material attributes and process controls. Skibsted et al. [20] have demonstrated how two MSPC‐based models derived from data measured by two
NIR instruments were used to provide an early warning during granulation
and to separate good batches from potentially bad batches.

2.4 General Scientific Considerations
for Model Development
Model building typically includes the following steps [21]. These steps are usually executed in a sequential manner, but many times it may be necessary to
return to an earlier step, thus imparting an iterative nature of this process. The
overall steps are as follows:
●●
●●

Defining the purpose/objective of the model.
Deciding on the type of modeling approach (e.g., mechanistic, empirical, or
hybrid) and the experimental methodology that would be used to support
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●●
●●

●●

●●

the model development. Since any model is based on a number of assumptions, it is important to understand at this stage the limitations of these
assumptions in order to correctly design the experiments and to interpret
the model results.
Collecting experimental data to support model development.
Developing model relationships, based on the scientific understanding of the
process and the collected experimental data.
Assessing the validity of the model prior to implementation, by both internal
metrics and external validation.
◦ Internal validation involves comparing model prediction with the actual
values, using the same data set that was used to build the model. Various
techniques such as cross‐validation, random (Monte Carlo) resampling,
and boot strapping can be used for internal validation [20].
◦ External validation involves verification of model results with independent data set(s), that is, data that was not used to build the model. Verification
of the model with an appropriate data set is especially important for
empirical models to demonstrate the robustness of such models. Model
validity is typically measured in terms of goodness of fit.
Documenting model results including initial assumptions and developing
plans for maintaining and updating the model throughout the life cycle of
the product.

Additionally, some specific considerations are warranted when considering
the implementation of models for specific purposes, as discussed in the following text.
2.4.1 Models for Process Characterization

Process characterization models can include models for process optimization
(e.g., reaction kinetics model), design space determination, and scale‐up. Since
the term design space in general refers to a multidimensional hyperspace, it is
important that models defining a design space consider multivariate interactions. In addition, for both mechanistic and empirical models, significant
uncertainty can exist in the model predictions, due to the underlying assumptions and simplifications used in model derivation, variabilities in measurements in the supportive data, and error in the model fit. Evaluation of
uncertainty in a design space model can lead to a more robust design space and
can help identify appropriate risk mitigation steps when moving to areas of
uncertainty.
Typically, if a model to define design space is developed based on laboratory
or pilot scale data, it is then verified at commercial scale. Verification approaches
in general consider the scale dependencies of the model parameters, the modeling approach (i.e., mechanistic or empirical), and the control strategy.
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2.4.2

Models for Supporting Analytical Procedures

This category includes models used to support various PAT‐based methods.
In general, these are data‐driven chemometric models such as PCA or PLS.
These models often have the flexibility to handle noisy measurements, missing data sets, and highly correlated variables. A primary consideration when
developing such models is the quality of data used to derive and to validate the
model. To make a robust chemometric model, the data set should include an
appropriate range of variability. For example, chemometric models meant to
span a design space should contain data representative of variations within the
design space.
2.4.3

Models for Process Monitoring and Control

When developing models for process monitoring and control, it is important
to consider all pertinent quality attributes and in‐process measurements using
techniques such as risk assessment. For example, if prediction from an empirical model (e.g., LV model) is used to ensure that the process is manufacturing
desired quality product when operating within the design space, it is desired to
include all expected sources of variability during the model‐defining stage.
Including variations helps ensure that the model would be applicable to all
regions within the entire design space for occurrences of material and process
parameter variability. Alternatively, if the objective is to control the process in
a narrow range near the target operating condition using an LV model, the
model could be constructed using batches manufactured only near the target
condition.

2.5 Scientific Considerations for
Maintenance of Models
Typically, models may need to be updated due to an instrument or process
drift. Additionally, unaccounted for variability (e.g., changes in raw material)
could result in out‐of‐spec predictions from the model. Consequently, it can
be valuable to monitor the performance of the model over the life cycle of the
product. An approach for monitoring model performance could include periodic comparison of model prediction with a reference method. This approach
would allow making adjustments to the model (e.g., recalibration) before failures occur.
The approach of model maintenance and update is relative to the model
implementation strategy (i.e., importance of the model in the control strategy
and its potential to affect product quality). Clear metrics for model update can
be established depending on the level of risk of the model.
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2.6 Conclusion
In the QbD paradigm, mathematical models can be an important tool for
leveraging pharmaceutical process understanding and can be applicable

throughout development and manufacturing including process development,
scale‐up, process monitoring, and continual improvement. Use of models can
support efficient development and implementation of a robust process that
ensures consistent manufacture of desired quality product. Although many
such models have been implemented in pharmaceutical process development
and manufacture, by and large these modeling approaches are still evolving
and more understanding is expected to be garnered in the coming years.
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